Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022;12(2):477-493.
doi: 10.3233/JPD-212976.

Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson's Disease: Past, Present, and Future

Yu-Yan Tan  1 , Peter Jenner  2 , Sheng-Di Chen  1   3
Affiliations
Review

Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson's Disease: Past, Present, and Future

Yu-Yan Tan et al. J Parkinsons Dis. 2022.

Abstract

Monoamine oxidase-B (MAO-B) inhibitors are commonly used for the symptomatic treatment of Parkinson's disease (PD). MAO-B inhibitor monotherapy has been shown to be effective and safe for the treatment of early-stage PD, while MAO-B inhibitors as adjuvant drugs have been widely applied for the treatment of the advanced stages of the illness. MAO-B inhibitors can effectively improve patients' motor and non-motor symptoms, reduce "OFF" time, and may potentially prevent/delay disease progression. In this review, we discuss the effects of MAO-B inhibitors on motor and non-motor symptoms in PD patients, their mechanism of action, and the future development of MAO-B inhibitor therapy.

Keywords: Monoamine oxidase-B inhibitors; Parkinson’s disease; rasagiline; safinamide; selegiline.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interests.

Figures

Fig. 1
Fig. 1
Selection of MAO-B inhibitors according to PD related symptoms.
See this image and copyright information in PMC

References

    1. Hayes MT (2019) Parkinson’s disease and parkinsonism. Am J Med 132, 802–807. - PubMed
    1. Dickson DW (2018) Neuropathology of Parkinson disease. Parkinsonism Relat Disord 46(Suppl 1) S30–S33. - PMC - PubMed
    1. Raza C, Anjum R, Shakeel N (2019) Parkinson’s disease: Mechanisms, translational models and management strategies. Life Sci 226, 77–90. - PubMed
    1. (2018) Global, regional, and national burden of Parkinson’s disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 17, 939–953. - PMC - PubMed
    1. Santos García D, de Deus Fonticoba T, Suárez Castro E, Borrué C, Mata M, Solano Vila B, CotsForaster A, Álvarez Sauco M, Rodríguez Pérez P, Vela L, Macías Y, Escalante S, Esteve P, Reverté Villarroya S, Cubo E, Casas E, Arnaiz S, Carrillo Padilla F, Pueyo Morlans M, Mir P, Martinez-Martin P (2019) Non-motor symptomsburden, mood, and gait problems are the most significant factorscontributing to a poor quality of life in non-demented Parkinson’sdisease patients: Results from the COPPADIS Study Cohort. Parkinsonism Relat Disord 66, 151–157. - PubMed

Publication types

MeSH terms